# Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

> **NCT02616029** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 66 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** E/C/F/TAF

## Key facts

- **NCT ID:** NCT02616029
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-17
- **Primary completion:** 2018-10-11
- **Final completion:** 2019-07-11
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2020-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02616029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02616029, "Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02616029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*